Recent Price Movement and Market Context
On 16 Mar 2026, Alembic Pharmaceuticals Ltd. recorded its lowest price in the past year at Rs.670.35. This new low comes after four consecutive days of declines, during which the stock lost 5.53% in returns. Despite this, the stock marginally outperformed its sector by 0.47% on the day of the new low. The share price currently trades below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a sustained bearish trend.
The broader market backdrop has also been subdued. The Sensex opened lower at 74,415.79, down 148.13 points (-0.2%), and was trading near 74,509.80 (-0.07%) at the time. The index remains 4.14% above its own 52-week low of 71,425.01 and has experienced an 8.34% decline over the past three weeks. The Sensex is trading below its 50-day moving average, which itself is positioned below the 200-day moving average, indicating a bearish market phase.
Performance Comparison and Historical Returns
Over the last year, Alembic Pharmaceuticals Ltd. has underperformed the Sensex significantly. The stock posted a negative return of -18.45%, while the Sensex managed a modest gain of 0.92% over the same period. The stock’s 52-week high was Rs.1,107.80, highlighting the extent of the decline from its peak. Furthermore, Alembic has lagged behind the BSE500 index across multiple time frames, including the last three years, one year, and three months, underscoring persistent underperformance relative to broader market benchmarks.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Financial Metrics and Profitability Trends
Long-term growth metrics for Alembic Pharmaceuticals Ltd. have been subdued. The company’s operating profit has declined at an annualised rate of -8.78% over the past five years, reflecting challenges in expanding profitability. The December 2025 results were largely flat, indicating limited near-term momentum.
Key ratios highlight some areas of concern. The inventory turnover ratio for the half-year period stands at a low 2.79 times, suggesting slower movement of stock. The debt-equity ratio, while modest at 0.28 times, is the highest recorded for the company in the recent half-year period. Quarterly earnings per share (EPS) have also been at a low Rs.6.77, pointing to pressure on profitability.
Balance Sheet Strength and Valuation Metrics
Despite the challenges, Alembic Pharmaceuticals Ltd. maintains a strong ability to service its debt, with a low Debt to EBITDA ratio of 0.90 times. The company’s return on capital employed (ROCE) is 12.6%, which is a positive indicator of capital efficiency. Valuation metrics also suggest the stock is trading at a discount relative to its peers, with an enterprise value to capital employed ratio of 2.2, which is considered attractive in the sector context.
Profit growth over the past year has been positive, with an 11.7% increase, although this has not translated into share price gains. The price/earnings to growth (PEG) ratio stands at 1.7, indicating moderate valuation relative to earnings growth expectations.
Institutional Holdings and Market Sentiment
Institutional investors hold a significant stake in Alembic Pharmaceuticals Ltd., with 20.41% of shares owned by these entities. This level of institutional holding reflects a degree of confidence in the company’s fundamentals from investors with substantial analytical resources.
Technical Indicators and Market Signals
Technical analysis of Alembic Pharmaceuticals Ltd. reveals predominantly bearish signals. The Moving Average Convergence Divergence (MACD) indicator is bearish on both weekly and monthly charts. Bollinger Bands also indicate bearish trends over these time frames. The Relative Strength Index (RSI) does not currently signal any strong momentum, remaining neutral on weekly and monthly periods.
Other technical tools such as the Know Sure Thing (KST) indicator and Dow Theory assessments show mild bearishness on weekly and monthly charts. The On-Balance Volume (OBV) indicator similarly reflects mild bearish sentiment, suggesting that trading volumes are not supporting upward price movement.
Holding Alembic Pharmaceuticals Ltd. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Key Concerns and Market Position
Alembic Pharmaceuticals Ltd.’s recent decline to a 52-week low of Rs.670.35 reflects a combination of subdued financial performance, underwhelming profit growth, and technical weakness. The stock’s consistent underperformance relative to the Sensex and BSE500 indices over multiple time frames highlights ongoing challenges in delivering shareholder returns.
While the company maintains a solid balance sheet with manageable debt levels and reasonable capital efficiency, these factors have not been sufficient to counterbalance the negative price momentum and cautious market sentiment. The stock’s valuation discount relative to peers suggests that the market is pricing in these concerns.
Overall, the current price level represents a significant point in Alembic Pharmaceuticals Ltd.’s trading history, underscoring the need for close monitoring of both financial results and market developments.
Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today
